SCHEMBL1009130

SCHEMBL1009130

CCOC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1.NS(=O)(=O)c1cc(C=O)ccc1Cl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 2/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
RXFP1 Q9HBX9 1/20 0.51
NPC1 O15118 4/20 0.50
RAB9A P51151 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
CA1 P00915 4/20 0.48
CA2 P00918 4/20 0.48
CA12 O43570 3/20 0.48
CA9 Q16790 2/20 0.48
CA5A P35218 1/20 0.48
CA6 P23280 1/20 0.48
CA7 P43166 1/20 0.48
CA13 Q8N1Q1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL941127 0.90 ALDH1A1 (0.66) ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A
SCHEMBL939715 0.79 ALDH1A1 (0.55) ALDH1A1RAB9AL3MBTL1CA1CA2
SCHEMBL3471632 0.78 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2KMT2ARAB9AL3MBTL1
SCHEMBL14593012 0.78 ALDH1A1 (0.67) ALDH1A1SMN1; SMN2KMT2ARAB9AL3MBTL1
SCHEMBL11412681 0.77 CA1 (0.53) ALDH1A1SMN1; SMN2NPC1RAB9AL3MBTL1
SCHEMBL27652100 0.76 CA2 (0.57) ALDH1A1SMN1; SMN2MEN1KMT2ACA1
Hydrochloric Acid SCHEMBL11499380 0.75 NPSR1 (0.56) ALDH1A1SMN1; SMN2NPSR1MEN1KMT2A
SCHEMBL3865205 0.75 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2NPSR1L3MBTL1CA1
SCHEMBL21962449 0.74 CA2 (0.54) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL9921935 0.74 CA12 (0.53) ALDH1A1SMN1; SMN2NPC1RAB9ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268612-B1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2014-08-20 EP disclosed
US-20130096105-A1 ArylSulfonamide Based Matrix Metalloprotease Inhibitors NOVARTIS AG (CH) 2013-04-18 US disclosed
EP-2268612-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS Novartis AG (CH) 2011-01-05 EP disclosed
WO-2009118292-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2009-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096105-A1 ArylSulfonamide Based Matrix Metalloprotease Inhibitors MMP11, MMP9, MMP10 ALDH1A1 816/4885SMN1; SMN2 1567/4885NPSR1 691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.